I do wonder, @benelong, if future off-label use might potentially also include IBD and UC (ulcerative coloitis) and other terrible diseases which are related. Didn’t Dr. Lightner get very good results in her Ph II trial? The size of the market is also much bigger (70-80% of our immune cells reside in the GI gut).
https://pubmed.ncbi.nlm.nih.gov/37661485/
https://pubmed.ncbi.nlm.nih.gov/33216484/
https://www.crohnscolitisfoundation.org/blog/regenerative-medicine-provides-hope-ibd-patients-with-perianal-disease
https://classic.clinicaltrials.gov/ct2/show/NCT04543994
banter and General Discussion, page-9794
-
- There are more pages in this discussion • 1,276 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
0.035(3.21%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.13 | $1.07 | $3.910M | 3.535M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 27197 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 43578 | 3 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |